Nexalin Technology (NXL) EBT Margin (2021 - 2026)
Nexalin Technology's (NXL) quarterly EBT Margin came in at 14025.67% in Q1 2026, down 918039.0% year-on-year from N/an in Q1 2025, and down 914.47% quarter-over-quarter from 1382.56% in Q4 2025.
Nexalin Technology (NXL) EBT Margin (2021 - 2026) Analysis & Trends
Nexalin Technology's EBT Margin history runs 6 years deep, the most recent figure standing at 14025.67% for Q1 2026.
- On a quarterly basis, EBT Margin fell 918039.0% year-over-year to 14025.67% in Q1 2026; TTM through Mar 2026 was 3022.94%, a 349866.0% increase from a year earlier, with the FY2025 full-year figure at 2725.42%, up 178332.0% from the prior year.
- EBT Margin declined to 14025.67% in Q1 2026 per NXL's latest filing, from 1382.56% in the prior quarter.
- Across five years, EBT Margin topped out at 55.68% in Q3 2022 and bottomed at 14025.67% in Q1 2026.
- The 5-year median for EBT Margin is 2449.0% (2023), against an average of 4630.33%.
- Across the five-year window, EBT Margin plunged 947108 bps in 2023 and jumped 902483 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 1988.34% in 2022, then sank by 91 bps to 3801.47% in 2023, then plunged by 174 bps to 10407.39% in 2024, then jumped by 87 bps to 1382.56% in 2025, then tumbled by 914 bps to 14025.67% in 2026.
- Per Business Quant, the three latest NXL EBT Margin figures stand at 14025.67% (Q1 2026), 1382.56% (Q4 2025), and 12542.35% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | -14,025.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,025.67% |
| Dec 31, 2025 | -1,382.56% |
| Sep 30, 2025 | -12,542.35% |
| Jun 30, 2025 | -2,239.74% |
| Mar 31, 2025 | -4,845.27% |
| Dec 31, 2024 | -10,407.39% |
| Sep 30, 2024 | -6,795.30% |
| Jun 30, 2024 | -4,780.93% |
| Mar 31, 2024 | -1,330.78% |
| Dec 31, 2023 | -3,801.47% |
| Sep 30, 2023 | -9,526.77% |
| Jun 30, 2023 | -2,314.12% |
| Mar 31, 2023 | -2,449.00% |
| Dec 31, 2022 | -1,988.34% |
| Sep 30, 2022 | -55.68% |
| Jun 30, 2022 | -108.64% |
| Mar 31, 2022 | -121.63% |
| Dec 31, 2021 | -2,152.63% |
| Sep 30, 2021 | -3,256.43% |